Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 8
2012 21
2013 29
2014 44
2015 58
2016 60
2017 57
2018 51
2019 75
2020 66
2021 17
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

423 results
Results by year
Filters applied: . Clear all
Page 1
Discordance of PIK3CA and TP53 mutations between breast cancer brain metastases and matched primary tumors.
Thulin A, Andersson C, Werner Rönnerman E, De Lara S, Chamalidou C, Schoenfeld A, Kovács A, Fagman H, Enlund F, Linderholm BK. Thulin A, et al. Sci Rep. 2021 Dec 7;11(1):23548. doi: 10.1038/s41598-021-02903-x. Sci Rep. 2021. PMID: 34876602 Free PMC article.
There is limited knowledge of the biology of breast cancer (BC) brain metastasis (BM). We primarily aimed to determine the mutations in BCBM and to compare the mutational pattern with the matched primary breast cancer (BC). ...We investigated 57 BCBMs, including 46 …
There is limited knowledge of the biology of breast cancer (BC) brain metastasis (BM). We primarily aimed to determine the mutations …
Independent somatic evolution underlies clustered neuroendocrine tumors in the human small intestine.
Elias E, Ardalan A, Lindberg M, Reinsbach SE, Muth A, Nilsson O, Arvidsson Y, Larsson E. Elias E, et al. Nat Commun. 2021 Nov 4;12(1):6367. doi: 10.1038/s41467-021-26581-5. Nat Commun. 2021. PMID: 34737276 Free PMC article.
Small intestine neuroendocrine tumor (SI-NET), the most common cancer of the small bowel, often displays a curious multifocal phenotype with several tumors clustered together in a limited intestinal segment. ...We conclude that primary multifocal SI-NETs generally arise fr …
Small intestine neuroendocrine tumor (SI-NET), the most common cancer of the small bowel, often displays a curious multifocal phenoty …
IMPROVED AGE- AND GENDER-SPECIFIC RADIATION RISK MODELS APPLIED ON COHORTS OF SWEDISH PATIENTS.
Andersson M, Eckerman K, Pawel D, Almén A, Mattsson S. Andersson M, et al. Radiat Prot Dosimetry. 2021 Oct 12;195(3-4):334-338. doi: 10.1093/rpd/ncab075. Radiat Prot Dosimetry. 2021. PMID: 34056661 Free PMC article.
METHODS: Calculations are performed on Swedish groups of patients with Paget's disease and with bone metastases from prostatic cancer and diagnosed with bone scintigraphy with an administration of 500 MBq 99mTc-phosphonate. RESULTS: The inclusion of patient survival rates …
METHODS: Calculations are performed on Swedish groups of patients with Paget's disease and with bone metastases from prostatic cancer
IDAC-ALPHA: AN ALPHA DOSIMETRY SOFTWARE FOR NORMAL ORGANS AND TISSUES.
Andersson M, Kluge A, Meyer T, Koumarianou E, Mattsson S. Andersson M, et al. Radiat Prot Dosimetry. 2021 Oct 12;195(3-4):327-333. doi: 10.1093/rpd/ncab046. Radiat Prot Dosimetry. 2021. PMID: 33839784
Radiopharmaceuticals have been used for the treatment of various forms of cancer since the 1940s. In recent years, the advantages of alpha emitting radionuclides have emerged as a favourable treatment option. ...The novel dosimetry model was applied to 223Ra-dichloride, fr …
Radiopharmaceuticals have been used for the treatment of various forms of cancer since the 1940s. In recent years, the advantages of …
The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma.
Ny L, Jespersen H, Karlsson J, Alsén S, Filges S, All-Eriksson C, Andersson B, Carneiro A, Helgadottir H, Levin M, Ljuslinder I, Olofsson Bagge R, Sah VR, Stierner U, Ståhlberg A, Ullenhag G, Nilsson LM, Nilsson JA. Ny L, et al. Nat Commun. 2021 Aug 27;12(1):5155. doi: 10.1038/s41467-021-25332-w. Nat Commun. 2021. PMID: 34453044 Free PMC article. Clinical Trial.
Preclinical studies have suggested that epigenetic therapy could enhance immunogenicity of cancer cells. We report the results of the PEMDAC phase 2 clinical trial (n = 29; NCT02697630) where the HDAC inhibitor entinostat was combined with the PD-1 inhibitor pembrolizumab …
Preclinical studies have suggested that epigenetic therapy could enhance immunogenicity of cancer cells. We report the results of the …
423 results